News & Media | Lee's Pharmaceutical
20 DEC 2018

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……





News & Media

Archive

29/10/2010
Grand Opening of Headquarters of Powder Pharmaceuticals
[Hong Kong] Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, announced that its associated company Powder Pharmaceuticals, Incorporated (PPI) has opened a headquarters at the Hong Kong Science and Technology Park on 29 October 2010. This is PPI’s first manufacturing facility in Hong Kong, which will strengthen its foundation for the development of Zingo, a novel pharmaceutical product for pain management.

Located on the ground floor of the Wireless Centre at the Hong Kong Science and Technology Park in Shatin, the office covers an area of over 13,000 square feet with total 14 staffs. PPI is owned by Lee’s Pharmaceuticals, China Opportunity, a renowned fund in China and Sigma-tau. PPI acquire certain assets of and the global interest in Zingo and its powder intradermal injection system. Zingo, also named Lidocaine Hydrochloride Monohydrate, is a new kind of analgesic applied on intact skin to provide painkilling effect prior to venipuncture and intravenous cannulation. Zingo, which has received approval for sales from Food and Drug Administration (FDA) in the United States, is used for partial analgesia prior to veni-puncture and intravenous cannulation for both kids and adults. PPI will focus on manufacturing, developing and selling Zingo and related products.

Mr. Geoffrey F. Woodhead, Assistant Commissioner of Innovation and Technology Commission, Mr. E Anthony Tan, CEO of Hong Kong Science and Technology Park, Mr. Ugo Di Francesco, CEO of Sigma-tau, Mr. Niccolo Magnoni and Mr. Fabio De Rosa, Director of PPI, together with Board members of Lee’s Pharmaceutical, Mr. Lee Siu Fong, Chairman of Lee’s Pharmaceutical, Ms. Leelalertsuphakun Wanee, Dr. Benjamin Li and Mr. Mauro Bove, hosted the grand opening ceremony.

Dr. Benjamin Li, CEO of Lee’s Pharmaceutical said, “I am very pleased to witness the establishment of PPI’s first manufacturing base and would like to extend my gratitude to my partner for its continuous support and trust. The opening marks the success of the production and development business of Lee’s Pharmaceutical. The Board expects the business of PPI to grow in the medium to long run. This transaction represents a good investment opportunity for the Group and a more solid foundation for future growth.”
[Hong Kong] Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, announced that its associated company Powder Pharmaceuticals, Incorporated (PPI) has...

22/12/2008
Anhui Government Official Visited Zhaoke Pharmaceutical (Hefei) Co. Ltd.
2008年12月22日晚9点,安徽省委常委、合肥市委书记孙金龙率省市及高新区领导一行20余人,视察了兆科药业(合肥)有限公司,孙书记对于公司的建设和发展以及取得的成就给予了高度的评价。
在公司的会议室,孙书记等省市领导兴致勃勃地听取了公司董事长李小羿博士对公司目前经营状况、发展目标、竞争优势,以及在新产品研发等方面的介绍。
孙书记还详细询问了公司在研新药的情况及发展前景,同时非常关心公司在发展过程中碰到什么困难,需要政府哪方面的支持。李博士向孙书记汇报了公司在科技项目投入方面的工作和取得的进展,并与孙书记进行了深入的交流。孙书记对于生物制药这一高科技产业给予了高度评价,表示会加大对于公司科研项目的支持力度,希望兆科药业加快发展,争创国内国际一流企业。
视察结束后,孙书记与董事长李博士、常务副总陈跃生合影留念,勉励兆科药业把握发展机遇,开创更加美好的未来。
2008年12月22日晚9点,安徽省委常委、合肥市委书记孙金龙率省市及高新区领导一行20余人,视察了兆科药业(合肥)有限公司,孙书记对于公司的建设和发展以及取得的成就给予了高度的评价。
在公司的会议室,孙书记等省市领导兴致勃勃地听取了...

15/06/2005
Distribution Agreement to market Somatostatin
(Hong Kong, 15 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed an Agreement with GP-Pharm S.A., Spain for the distribution and marketing of Somonal®~Somatostatin 3mg ampoules, throughout Hong Kong and the People's Republic of China.

Somatostatin was first discovered in hypothalamic extracts and identified as a hormone that inhibited secretion of growth hormone. Subsequently, Somatostatin was found to be secreted by a broad range of tissues, including pancreas, intestinal tract and regions of the central nervous system outside the hypothalamus. Somonal® consists of Somatostatin freeze dried ampoules containing 3 mg of the active substance for dissolution purpose, is indicated for used clinically to treat carcinoid syndrome, enterocutaneous and pancreatic fistula, VIPomas, glucagonomas, severe esophageal varices bleeding.

Somatostatin is widely prescribed in China for acute variceal bleeding. Due to the high prevalence of HBV infection, China has a relatively high number of people suffered from cirrhosis and the subsequent acute esophageal varices bleeding caused by portal vein hypertension. The market for product like Somatostatin in China is quite attractive.

"We're extremely pleased to establish this distribution partnership with GP-Pharm S.A.,," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "This is the seventh product so far we have licensed-in for distribution in China from our partners in Italy and Spain. This product will allow the Group to enter into a new therapeutic area." The Group believe that successful implementation of this strategy will further expand its market shares, enrich its product pipeline and to broaden its revenue base.

About GP-Pharm

GP-Pharm P.A. is a pharmaceutical company based in Spain within the Lipotec Group whose foundation dates back from 2001. The company is undertaking the pharmaceutical and the clinical development of new products containing hormones and Cytotoxic drugs.

About Lee's

Lee's Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com
(Hong Kong, 15 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed an Agreement with GP-Pharm S.A., Spain for the distribution and marketing of Somonal®~Somatostatin 3mg ampoules, throughout...

29/03/2005
Market Isosorbide Mononitrate in HK and China
(Hong Kong, 29 March 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed a Supply and Distribution Agreement with Marvecs Services S.r.l. for the distribution and marketing of Vasdilat® slow-released capsules (Isosorbide Mononitrate), throughout Hong Kong and the People's Republic of China.

Vasdilat®~Isosorbide Mononitrate (ISMN), is a type of vasodilator with effects on both arteries and veins. The pain of coronary heart disease (angina) usually occurs when the heart requires more blood and oxygen than its blood vessels supplying the heart can deliver. Our ISMN capsule contains 30mg of isosorbide mononitrate in a slow-released formulation for oral administration, is indicated for the prevention and long-term treatment of angina pectoris associated with coronary artery disease. ISMN relaxes blood vessels, increasing the blood and oxygen supply to the heart. It reduces the pressure that the heart has to pump against and hence the Heart's work and need for oxygen, and also increases supply of oxygen to the heart by dilating the arteries which supply the heart itself. Isosorbide mononitrate is in the class of drugs called anti-anginal medications….
(Hong Kong, 29 March 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed a Supply and Distribution Agreement with Marvecs Services S.r.l. for the distribution and marketing of Vasdilat®...
know more
know more